Acute Thoracic Herpes Zoster, Erector Spinae Plane Block, Thoracic Paravertebral Block, Pain Relief
Conditions
Brief summary
The aim of this research is to study and compare the efficacy and safety of single injection erector spinae plane block and thoracic paravertebral block in prevention of post herpetic neuralgia in patients with acute thoracic herpes zoster.
Interventions
DRUGControl Rx
Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed
PROCEDUREErector Spinae Block
Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
PROCEDUREThoracic Paravertebral Block
Patients of this group will receive 25 mg bupivacaine 0.5% , plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at desired level under ultrasonography
Sponsors
Tanta University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
51 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Over 50 years of age * Chest wall herpetic eruption of less than one week * Moderate or severe pain
Exclusion criteria
* Patient refusal * Eruption more than one week duration * Patients who will not receive appropriate anti-viral therapy * Patients with mild pain * Infection at the site of injection * Patients with a history of renal, hepatic diseases, coagulopathy, steroid therapy, malignancies. * Patient taking chemotherapy and/or radiotherapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of post herpetic neuralgia (PHN) | 3 months | Persistent herpetic pain after 3 months will reported as post herpetic neuralgia (PHN) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analog Scale | 6 months | Visual Analog Scale (VAS) at baseline, 3, 4, 12, 24 weeks |
| Total consumption of rescue analgesia | 6 months | Rescue analgesia in the form of Acetaminophen in a dose of 1,000 mg will be given if Visual Analog Scale (VAS) ≥4 |
| The times of complete resolution of pain | 3 months | The times of complete resolution of pain (from the date of block until complete disappearance of herpetic pain) |
| Adverse effects and complications | 1 day | * Hypotension * Pneumothorax * Local anesthetic toxicity * Respiratory depression |
Countries
Egypt
Contacts
Primary ContactEsraa Hassan Abdelwahab, MSc
Outcome results
None listed